SPY734.10+0.15%QQQ656.44+1.45%BTC/USD75,864.77−0.13%DIA509.41−0.95%GLD372.10−0.90%TLT81.60−0.40%

Premium Services

cbdMD Inc

YCBDAMEX

Trade with Public

Trade with Public

$0.3880

-0.018-4.43%

Overview News Earnings ForecastPrice TargetsFinancials Sentiment Ownership Compare Stock Report

Connect With Us

About Benzinga

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

cbdMD (YCBD) Stock Price Target 2026

The average analyst price target for cbdMD is $2. The one analyst covering it rates it Buy. The latest change came on Aug 17, 2026, when Maxim Group downgraded cbdMD from Buy to Hold.

The Average Analyst Price Target for cbdMD is $2.

Price Target Range — 2 Quarters

Analyst Consensus — 1 Analysts

1Hold

Consensus RatingBuy# Analysts1Avg. Consensus PT$2

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for cbdMD Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 17, 2026	Maxim Group	Anthony Vendetti	Downgrade	Buy→Hold	—
Aug 20, 2025	Maxim Group	Tom McGovern	PT Cut	Buy	$3→$2
May 22, 2025	Maxim Group	Tom McGovern	PT Cut	Buy	$16→$3

Analyst Ratings News

PRO
Maxim Group Downgrades cbdMD to Hold

Maxim Group analyst Anthony Vendetti downgrades cbdMD (AMEX:YCBD) from Buy to Hold.

Benzinga Newsdesk

PRO
Maxim Group Maintains Buy on cbdMD, Lowers Price Target to $2

Maxim Group analyst Tom McGovern maintains cbdMD (AMEX:YCBD) with a Buy and lowers the price target from $3 to $2.

Benzinga Newsdesk

PRO
Maxim Group Initiates Coverage On cbdMD with Buy Rating, Announces Price Target of $3

Maxim Group analyst Anthony Vendetti initiates coverage on cbdMD (AMEX:YCBD) with a Buy rating and announces Price Target of $3.

Benzinga Newsdesk

Cantor Remains Neutral on Charlotte's Web, cbdMD and CV Science, Why These CBD Stocks May Benefit If Cannabis Reform Actually Happens

Cantor Fitzgerald released a new report analyzing the possible effects of CBD reform in the stock performance of Charlotte's Web Holdings (TSX: CWEB) (OTCQX: CWBHF), cbdMD (NYSE:

Natan Ponieman

Cantor Updates Ratings On Several Cannabis And CBD Stocks - MedMen, Jushi, cbdMD, CV Sciences

Cantor Fitzgerald’s Pablo Zuanic provided updated ratings and estimates on several stocks from the cannabis and CBD sector, those being – MedMen Enterprises (OTCQF:

Nina Zdinjak

10 Biggest Price Target Changes For Friday

Piper Sandler raised Adobe Inc. (NASDAQ: ADBE) price target from $570 to $600. Adobe shares rose 3.3% to $569.50 in pre-market trading.

Lisa Levin